دورية أكاديمية
Late Adverse Effects after Treatment for Childhood Acute Leukemia.
| العنوان: | Late Adverse Effects after Treatment for Childhood Acute Leukemia. |
|---|---|
| المؤلفون: | Roganovic J; Department of Pediatric Hematology and Oncology, Children's Hospital Zagreb, Zagreb, Croatia; Faculty of Biotechnology and Drug Development, University of Rijeka, Rijeka, Croatia., Haupt R; Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy., Bárdi E; St. Anna Childrens Hospital, Wien; Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria., Hjorth L; Department of Pediatrics, Skane University Hospital; Department of Clinical Sciences, Lund University, Lund, Sweden., Michel G; Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland., Pavasovic V; Department of Paediatric Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom., Scheinemann K; Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland; Division of Hematology-Oncology, Children's Hospital of Eastern Switzerland, St Gallen, Switzerland; Department of Pediatrics, McMaster Children's Hospital and McMaster University, Hamilton, Canada., van der Pal HJ; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Zadravec Zaletel L; Radiotherapy Department, Institute of Oncology Ljubljana, Ljubljana; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia,., Amariutei AE; Youth Cancer Europe, Cluj-Napoca, Romania., Skinner R; Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Royal Victoria Infirmary; Translational and Clinical Research Institute, and Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom.roderickskinner@nhs.net. |
| مؤلفون مشاركون: | PanCare Board |
| المصدر: | Acta medica academica [Acta Med Acad] 2024 Apr; Vol. 53 (1), pp. 59-80. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Akademija nauka i umjetnosti Bosne i Hercegovine Country of Publication: Bosnia and Herzegovina NLM ID: 101587903 Publication Model: Print Cited Medium: Internet ISSN: 1840-2879 (Electronic) Linking ISSN: 18401848 NLM ISO Abbreviation: Acta Med Acad Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Sarajevo : Akademija nauka i umjetnosti Bosne i Hercegovine |
| مواضيع طبية MeSH: | Leukemia, Myeloid, Acute*/therapy , Leukemia, Myeloid, Acute*/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy , Cancer Survivors*, Humans ; Child ; Hematopoietic Stem Cell Transplantation/adverse effects ; Long Term Adverse Effects/chemically induced ; Antineoplastic Agents/adverse effects |
| مستخلص: | The aim of this review is to raise awareness and knowledge among healthcare professionals and policymakers about late adverse effects in survivors of childhood leukemia. With contemporary treatment, over 90% of children with acute lymphoblastic leukemia (ALL) and over 60% with acute myeloid leukemia (AML) are cured. Large cohort studies demonstrate that 20% of ALL and most AML survivors have at least one chronic health condition by 20-25 years after diagnosis. These are life-changing or threatening in some survivors and contribute to increased premature mortality. We describe the frequency, causes, clinical features, and natural history of the most frequent and severe late adverse effects in childhood leukemia survivors, including subsequent malignant neoplasms, metabolic toxicity, gonadotoxicity and impaired fertility, endocrinopathy and growth disturbances, bone toxicity, central and peripheral neurotoxicity, cardiotoxicity, psychosocial late effects, accelerated ageing and late mortality. The wide range of late effects in survivors of haemopoietic stem cell transplant is highlighted. Recent developments informing the approach to long-term survivorship care are discussed, including electronic personalized patient-specific treatment summaries and care plans such as the Survivor Passport (SurPass), surveillance guidelines and models of care. The importance of ongoing vigilance is stressed given the increasing use of novel targeted drugs with limited experience of long-term outcomes. CONCLUSION: It is vital to raise awareness of the existence and severity of late effects of childhood leukemia therapy among parents, patients, health professionals, and policymakers. Structured long-term surveillance recommendations are necessary to standardize follow-up care. (Copyright © 2024 Roganovic et al. This article is available under a Creative Commons License (Attribution 4.0 International).) |
| References: | J Clin Endocrinol Metab. 2012 Oct;97(10):3584-92. (PMID: 22865901) Cancer. 2018 Mar 1;124(5):1044-1052. (PMID: 29338081) Pediatr Blood Cancer. 2013 Apr;60(4):543-9. (PMID: 23281199) Pediatr Blood Cancer. 2020 Sep;67(9):e28539. (PMID: 32618122) J Clin Oncol. 2018 Jul 20;36(21):2135-2144. (PMID: 29874141) J Clin Oncol. 2016 Oct 1;34(28):3440-50. (PMID: 27458300) Biol Blood Marrow Transplant. 2020 Apr;26(4):772-777. (PMID: 31669175) Eur J Cancer. 2021 Sep;154:316-328. (PMID: 34333209) Cancer. 2017 Nov 1;123(21):4207-4214. (PMID: 28654149) Lancet Haematol. 2019 Jun;6(6):e306-e316. (PMID: 31078468) Pediatr Blood Cancer. 2013 Dec;60(12):1988-95. (PMID: 24038890) Curr Opin Pediatr. 2018 Oct;30(5):628-638. (PMID: 30124579) J Clin Oncol. 2009 Jun 1;27(16):2677-85. (PMID: 19364965) Lancet. 2017 Dec 9;390(10112):2569-2582. (PMID: 28890157) Leukemia. 2001 Jan;15(1):41-5. (PMID: 11243397) Eur J Cancer. 2007 Aug;43(12):1778-80. (PMID: 17543517) Pediatr Blood Cancer. 2014 Jan;61(1):53-67. (PMID: 23940101) Lancet Oncol. 2006 Jun;7(6):489-98. (PMID: 16750499) J Cancer Surviv. 2019 Oct;13(5):759-772. (PMID: 31396878) Children (Basel). 2015 Apr 21;2(2):146-73. (PMID: 27417356) Lancet Diabetes Endocrinol. 2021 Sep;9(9):622-637. (PMID: 34339631) J Clin Oncol. 2013 Dec 20;31(36):4496-503. (PMID: 24248696) Osteoporos Int. 2016 Apr;27(4):1281-1386. (PMID: 26856587) Bone Marrow Transplant. 2000 Jan;25(2):191-6. (PMID: 10673679) J Clin Oncol. 2018 Jul 20;36(21):2190-2197. (PMID: 29874134) BMJ. 2009 Dec 08;339:b4606. (PMID: 19996459) Bone Marrow Transplant. 2010 Jan;45(1):79-85. (PMID: 19421172) Qual Life Res. 2018 Jun;27(6):1431-1443. (PMID: 29372438) J Clin Oncol. 2020 Oct 10;38(29):3418-3429. (PMID: 32706634) J Clin Oncol. 2010 Jan 10;28(2):324-31. (PMID: 19917844) Neurol Sci. 2021 Sep;42(9):3681-3686. (PMID: 33439396) Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):738-44. (PMID: 15936554) Lancet Oncol. 2014 Oct;15(11):1215-23. (PMID: 25239573) Eur J Cancer. 2019 Mar;110:86-97. (PMID: 30772657) Cancer Treat Rev. 2009 Nov;35(7):616-32. (PMID: 19640651) J Health Psychol. 2022 Mar;27(4):990-1005. (PMID: 33153307) Prog Pediatr Cardiol. 2014 Sep 1;36(1-2):19-26. (PMID: 26412958) J Clin Oncol. 1996 Oct;14(10):2826-35. (PMID: 8874345) Pediatr Blood Cancer. 2007 Jan;48(1):21-7. (PMID: 16317756) Adv Med Sci. 2014 Sep;59(2):200-5. (PMID: 25323758) JAMA Oncol. 2016 Oct 01;2(10):1277-1286. (PMID: 27254472) J Clin Oncol. 2006 Aug 20;24(24):3858-64. (PMID: 16921038) J Clin Oncol. 2001 Jul 1;19(13):3163-72. (PMID: 11432882) JAMA Oncol. 2017 Nov 01;3(11):1554-1557. (PMID: 28426850) Haematologica. 2015 May;100(5):e186-9. (PMID: 25616572) Med Pediatr Oncol. 2000 Oct;35(4):415-20. (PMID: 11025472) Pediatr Clin North Am. 2020 Dec;67(6):1103-1134. (PMID: 33131537) Eur J Endocrinol. 2017 Apr;176(4):R183-R203. (PMID: 28153840) Blood. 2008 Jun 15;111(12):5515-23. (PMID: 18334672) Curr Diab Rep. 2018 Apr 18;18(6):32. (PMID: 29671081) Best Pract Res Clin Endocrinol Metab. 2019 Jun;33(3):101291. (PMID: 31327697) Cardiol Young. 2015 Aug;25 Suppl 2:107-16. (PMID: 26377717) Lancet Oncol. 2021 Feb;22(2):e45-e56. (PMID: 33539753) Lancet Oncol. 2020 Mar;21(3):421-435. (PMID: 32066543) Pediatr Blood Cancer. 2015 Oct;62(10):1838-43. (PMID: 25970742) J Clin Oncol. 2018 Jul 20;36(21):2153-2159. (PMID: 29874130) Curr Treat Options Cardiovasc Med. 2016 Jul;18(7):47. (PMID: 27230282) Expert Rev Endocrinol Metab. 2019 Jan;14(1):49-61. (PMID: 30596296) Curr Treat Options Oncol. 2016 Sep;17(9):50. (PMID: 27476159) J Clin Oncol. 2021 Jun 1;39(16):1813-1823. (PMID: 33886350) J Child Psychol Psychiatry. 1988 Nov;29(6):839-52. (PMID: 3069852) J Clin Oncol. 2018 Jul 20;36(21):2145-2152. (PMID: 29874133) Eur J Cancer. 2018 Oct;102:69-81. (PMID: 30138773) Nat Rev Clin Oncol. 2014 Dec;11(12):740-50. (PMID: 25348788) Haematologica. 2013 May;98(5):744-52. (PMID: 23403323) Endocr Rev. 2019 Jun 1;40(3):711-767. (PMID: 30476004) Lancet Oncol. 2019 Apr;20(4):531-545. (PMID: 30797674) Br J Haematol. 2015 Sep;170(5):719-26. (PMID: 25974284) Lancet Oncol. 2017 Feb;18(2):e75-e90. (PMID: 28214419) Children (Basel). 2019 Nov 29;6(12):. (PMID: 31795500) Leukemia. 2021 Aug;35(8):2258-2273. (PMID: 33495497) Curr Treat Options Oncol. 2016 Apr;17(4):17. (PMID: 26951206) Ann Oncol. 2019 Jun 1;30(6):908-920. (PMID: 31111878) Bone Marrow Transplant. 2020 Oct;55(10):1985-1995. (PMID: 32231250) Pediatr Clin North Am. 2020 Dec;67(6):1069-1081. (PMID: 33131535) Pediatr Clin North Am. 2010 Feb;57(1):297-322. (PMID: 20307722) N Engl J Med. 2016 Mar 3;374(9):833-42. (PMID: 26761625) J Clin Endocrinol Metab. 2017 Jul 1;102(7):2242-2250. (PMID: 28368472) J Clin Oncol. 2006 Nov 20;24(33):5277-82. (PMID: 17088567) Dtsch Arztebl Int. 2017 Nov 24;114(47):805-812. (PMID: 29229046) Pediatr Blood Cancer. 2021 Jul;68(7):e29047. (PMID: 33860611) Bone Marrow Transplant. 2021 Jun;56(6):1422-1425. (PMID: 33454725) |
| فهرسة مساهمة: | Keywords: Acute Leukemia; Child; Late Effects; Long-Term Follow-Up; Survivor |
| المشرفين على المادة: | 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20240710 Date Completed: 20240710 Latest Revision: 20240714 |
| رمز التحديث: | 20240714 |
| مُعرف محوري في PubMed: | PMC11237916 |
| DOI: | 10.5644/ama2006-124.438 |
| PMID: | 38984700 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1840-2879 |
|---|---|
| DOI: | 10.5644/ama2006-124.438 |